The Medical Developments International Ltd (ASX: MVP) share price finished 9.3% higher by the end of the day after announcing to the market a trading update.
It said that in the first quarter of FY19 sales were up by 56% compared to the first quarter of FY18. Penthrox revenue was up 57% and respiratory device revenue was up 58%.
It also said that in-market sales in the UK were up 62% in the fourth quarter of FY18 compared to the third quarter of FY18 and in Ireland it was up 26% in the same time period.
The company said that it sold Penthrox to 436 UK & Ireland customers, compared to 191 customers a year ago. The new total included 125 hospitals.
Medical Developments also said that it sold to 272 French customers, which was a lot more than the 166 customers it had a year ago.
Management revealed that it has received the first Penthrox orders in 12 countries in Europe, including Germany. The first orders in Mexico, Saudi Arabia and Hong Kong are expected during FY19.
Back to the FY19 first quarter trading update, Penthrox sales to Australian ambulance services were up 7%, North American respiratory device market sales were up 98% and sales of Breath-A-Tech respiratory devices were 24% higher in Australia.
Management pointed to the fact that Penthrox has been approved in 26 countries since the start of the 2018 calendar year as a positive factor. By the end of the 2020 calendar year the company expects approvals in 77 countries including Russia and perhaps China.
The growth runway for Medical Developments has always been a long one – it’s only when it has been approved in all of the target countries will we get to see its true revenue potential. However, this update was a positive sign of progress.
However, it’s still trading at more than 80x FY20’s estimated earnings – so based on valuation I’ll be giving it a miss for now.
Instead, this exciting growth share looks good value to me – that’s why it’s in my portfolio.
You might not know this market leader's name, but it's rapidly expanding into a highly profitable niche market here in Australia. Even better, the shares boast a strong, fully franked dividend that should balloon in the years to come. In other words, we're looking at the holy grail of incredible long-term growth potential AND income you can watch accruing in your account in real time!
Simply click here to grab your FREE copy of this up-to-the-minute research report on our #1 dividend share recommendation now.
Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.